3The Collaborative Research Group for the Second Multi-center Survey of Clinical Management of Dyslipidemia in China.第二次中国临床血脂控制达标率及影响因素多中心协作研究[J].中华心血管病杂志,2007,35(5):420-427. 被引量：127
4Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular disease in the United States[J]. Circulation, 102:3137-3147.
5Jing L/Xi Lt Ojng W et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China Peace-retrospectvice acute myocardial infarction study):a retrospective analysis of hospital data[J]. Lancet, 2015, 385:441-451.
6Shuiping Z, Yongjun Wj Yiming Mj et al. Prevalence of dyslipideamia in patients treated with lipe-lowering agents in China: results of the dyslipidemia international study(DYSIS) [J]. Atherosclerosis, 2014, 235: 463-469.
7Boden WE, O' Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease[J]. N Engl J Med, 2007, 356: 1503-1516.
8Rezende PC, Hueb W, Garzillo CL, et al. Ten-year outcomes of patients randomized to surger)5 angioplasty, or medical treatment for stable multivessel coronary disease: effect of age in the Medicine, Angioplasty, or Surgery Study II trial[J]. J Thorac Cardiovasc Surg, 2013, 146: 1105-1112.
9The Writing Group for the Bypass Angioplasty Revascularization Investigation (BAR/) Investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: a multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BAKI) Investigators[J].JAMA, 1997, 277(9): 715-721.
10Myers J, Prakash M, Froelicher V, et al. Exercise capacity and mortality among men referred for exercise testing[J]. N Engl J Med, 2002, 346(11): 793-801.
